Subtopic Deep Dive
Cardiac Manifestations in Hypereosinophilic Syndrome
Research Guide
What is Cardiac Manifestations in Hypereosinophilic Syndrome?
Cardiac manifestations in hypereosinophilic syndrome (HES) refer to eosinophil-mediated endomyocardial damage, thrombosis, and fibrosis leading to restrictive cardiomyopathy and heart failure.
Hypereosinophilic syndrome involves persistent eosinophilia causing multi-organ damage, with cardiac involvement as a primary cause of mortality (Parrillo et al., 1979, 316 citations; Ogbogu et al., 2007, 371 citations). Key features include endocardial thickening, mural thrombi, and valvular dysfunction identified via echocardiography and MRI. Over 50 papers document these manifestations, emphasizing early detection for survival.
Why It Matters
Cardiac complications in HES account for up to 50% of deaths, necessitating prompt diagnosis through imaging and biomarkers (Parrillo et al., 1979; Ogbogu et al., 2007). Therapeutic interventions like steroids and imatinib target FIP1L1-PDGFRα fusions to prevent progression (Gotlib et al., 2003, 286 citations). Management guidelines reduce glucocorticoid use with biologics like mepolizumab, improving remission rates (Wechsler et al., 2017, 982 citations). These advances lower mortality in clinical practice (Klion, 2015, 273 citations).
Key Research Challenges
Early Detection of Subclinical Damage
Eosinophil infiltration causes silent endomyocardial fibrosis detectable only by advanced imaging before symptoms arise (Ogbogu et al., 2007). Biomarker limitations hinder risk stratification (Roufosse and Weller, 2010). Serial echocardiography misses early thrombi (Parrillo et al., 1979).
Heterogeneous Molecular Subtypes
HES variants like FIP1L1-PDGFRα-positive cases respond to tyrosine kinase inhibitors, unlike idiopathic forms (Gotlib et al., 2003). Molecular classification guides therapy but requires genetic testing (Klion, 2015). Overlap with EGPA complicates diagnosis (Wechsler et al., 2017).
Long-term Therapeutic Monitoring
Relapse after steroid tapering demands vigilant eosinophil counts and cardiac imaging (Weller and Bubley, 1994, 937 citations). Biologic efficacy varies, with incomplete data on cardiac-specific outcomes (Wechsler et al., 2017). Adverse events from prolonged immunosuppression persist (Klion, 2015).
Essential Papers
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Michael E. Wechsler, Praveen Akuthota, David Jayne et al. · 2017 · New England Journal of Medicine · 982 citations
In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more weeks in remission and a higher proportion of participants in remission than did place...
The idiopathic hypereosinophilic syndrome
PF Weller, Glenn J. Bubley · 1994 · Blood · 937 citations
Abstract THE IDIOPATHIC hypereosinophilic syndrome (HES) is a leukoproliferative disorder, or more likely disorders, marked by a sustained overproduction of eosinophils. The distinctiveness of the...
Eosinophilic gastrointestinal disorders (EGID)
Marc E. Rothenberg · 2004 · Journal of Allergy and Clinical Immunology · 908 citations
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Juan Luis Steegmann, Michele Baccarani, Massimo Breccia et al. · 2016 · Leukemia · 462 citations
Cardiovascular Manifestations of Hypereosinophilic Syndromes
Princess U. Ogbogu, Douglas R. Rosing, McDonald K. Horne · 2007 · Immunology and Allergy Clinics of North America · 371 citations
Practical approach to the patient with hypereosinophilia
Florence Roufosse, Peter F. Weller · 2010 · Journal of Allergy and Clinical Immunology · 316 citations
The cardiovascular manifestations of the hypereosinophilic syndrome
Joseph E. Parrillo, Jeffrey Borer, Walter L. Henry et al. · 1979 · The American Journal of Medicine · 316 citations
Reading Guide
Foundational Papers
Start with Parrillo et al. (1979) for classic cardiovascular descriptions via echocardiography; Weller and Bubley (1994) for HES definition and multi-organ context; Ogbogu et al. (2007) for comprehensive manifestations review.
Recent Advances
Wechsler et al. (2017) on mepolizumab remission; Klion (2015) on treatment strategies; Roufosse and Weller (2010) for diagnostic approaches.
Core Methods
Echocardiography for endocardial changes; cardiac MRI for fibrosis; biopsy for histopathology; molecular testing for FIP1L1-PDGFRα fusions; eosinophil counts for monitoring (Parrillo 1979; Gotlib 2003).
How PapersFlow Helps You Research Cardiac Manifestations in Hypereosinophilic Syndrome
Discover & Search
Research Agent uses searchPapers for 'cardiac manifestations hypereosinophilic syndrome' yielding Ogbogu et al. (2007), then citationGraph reveals 371 citing works including Klion (2015), and findSimilarPapers expands to related EGPA trials like Wechsler et al. (2017). exaSearch uncovers histopathological imaging studies across 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract echocardiographic findings from Parrillo et al. (1979), verifies claims with CoVe against Weller and Bubley (1994), and runs PythonAnalysis on citation data with pandas for mortality trend stats. GRADE grading scores evidence as high for mepolizumab remission (Wechsler et al., 2017).
Synthesize & Write
Synthesis Agent detects gaps in FIP1L1-PDGFRα cardiac outcomes via contradiction flagging across Gotlib et al. (2003) and Klion (2015), then Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10+ refs, and latexCompile for PDF. exportMermaid visualizes disease progression timelines.
Use Cases
"Analyze survival rates in HES cardiac cohorts from 1979-2020 papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted cohort data from Ogbogu 2007/Parrillo 1979) → Kaplan-Meier plot output with statistical p-values.
"Draft LaTeX review on HES endomyocardial fibrosis management"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Wechsler 2017, Klion 2015) + latexCompile → camera-ready PDF with figures.
"Find code for HES eosinophil count risk models"
Research Agent → paperExtractUrls (Klion 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect → R script for logistic regression on cardiac risk stratification.
Automated Workflows
Deep Research workflow scans 50+ HES papers via searchPapers → citationGraph → structured report on cardiac mortality trends (Parrillo 1979 to Wechsler 2017). DeepScan applies 7-step CoVe with GRADE checkpoints to verify fibrosis mechanisms in Ogbogu et al. (2007). Theorizer generates hypotheses on mepolizumab's cardiac protection from Klion (2015) trial data.
Frequently Asked Questions
What defines cardiac manifestations in HES?
Eosinophil-driven endomyocardial damage progresses from necrosis to thrombosis and fibrosis, causing restrictive cardiomyopathy (Parrillo et al., 1979; Ogbogu et al., 2007).
What are key diagnostic methods?
Echocardiography detects endocardial thickening; cardiac MRI identifies thrombi; endomyocardial biopsy confirms eosinophilic infiltration (Roufosse and Weller, 2010).
Which papers are foundational?
Weller and Bubley (1994, 937 citations) defines HES; Parrillo et al. (1979, 316 citations) details cardiovascular features; Ogbogu et al. (2007, 371 citations) reviews manifestations.
What open problems remain?
Optimal timing for biologics like mepolizumab in subclinical cardiac HES; long-term outcomes of FIP1L1-PDGFRα inhibitors on fibrosis reversal; imaging biomarkers for early risk stratification (Klion, 2015; Gotlib et al., 2003).
Research Eosinophilic Disorders and Syndromes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cardiac Manifestations in Hypereosinophilic Syndrome with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers